Month: April 2024

Reference is made to the announcement by Ensurge Micropower ASA (the “Company”) on 19 March 2024 relating to the approved 5:1 share consolidation (reverse share split) in the Company. The share consolidation has now been duly registered with the Norwegian Register of Business Enterprises. The Company’s share capital is NOK 273,877,727 divided into 547,755,454 shares, each share having a par value of NOK 0.50. For the avoidance of doubt, the above registration does not affect the dates set forth in the key information announcement published by the Company on 19 March 2024. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

METTAWA, Ill., April 04, 2024 (GLOBE NEWSWIRE) — Brunswick Corporation (NYSE: BC) will release its first quarter financial results on Thursday, April 25, 2024 before the market opens by way of an advisory release, notifying the public that the complete and full-text results will be available on the Company’s website at https://ir.brunswick.com.  The results will also be available on the SEC’s website with the Form 8-K filing of the release at http://goo.gl/wJQN1.  The Company will hold a conference call at 10 a.m. CST/ 11 a.m. EST, Thursday, April 25, 2024, hosted by David M. Foulkes, chief executive officer, Ryan M. Gwillim, executive vice president and chief financial and strategy officer and Neha Clark, senior vice president, enterprise finance.  A copy of the presentation to be used on this call will be available when the...

Planegg/Martinsried, April 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the Company has been issued a patent by the European Patent Office protecting its inducible Medigene T cell receptor (iM-TCR) technology, which contains a control mechanism to regulate efficacy and improve safety of its T cell receptor engineered T cell (TCR-T) therapies. “Over the past years we have conscientiously built an extensive international intellectual property portfolio across major markets, which we expect will provide a significant competitive advantage. Each technology we design and develop aims to enhance efficacy and mitigate safety risk to the patient and is based on our extensive immunology research...

Availability of the information relating to the Ordinary Shareholders’ Meeting of April 26, 2024 Paris, April 4, 2024 – The Ordinary Shareholders’ Meeting of Lectra will take place on Friday April 26, 2024 at 9:30 a.m. (CET), at the head office situated at 16-18 rue Chalgrin, 75016 Paris. The notice of meeting (avis de reunion valant avis de convocation), which was published in the French Bulletin des Annonces Légales Obligatoires (BALO) dated March 20, 2024, bulletin n°35, includes the agenda, the draft resolutions submitted to this Shareholders’ Meeting and the conditions for participation and exercise of voting rights. All the documents relating to this Shareholders’ Meeting, as referred to in Article R.22-10-23 of the French Commercial Code, are available online and can be downloaded directly on the Lectra website: https://www.lectra.com/en/investors/shareholder-information/shareholders-meetings. The...

April 4, 2024Announcement no. 6 Notice convening the Annual General Meeting in BioPorto A/S The Board of Directors hereby convenes the Annual General Meeting of BioPorto A/S (“BioPorto” or the “Company”) to be held on: Tuesday April 30, 2024, at 3.00 p.m. (CEST)At the Company’s addressTuborg Havnevej 15, st., DK-2900 Hellerup, Denmark AGENDA: ITEM 1 – REPORT ON THE COMPANY’S ACTIVITIES DURING THE PAST YEAR The Board of Directors proposes that the Board’s report on the Company’s activities for the past year be noted. ITEM 2 – PRESENTATION OF THE ANNUAL REPORT FOR APPROVAL AND ALLOCATION OF PROFIT OR COVERING OF LOSS The Board of Directors proposes that the annual report be approved and that the result for the financial year 2023 be carried forward to the next financial year. ITEM 3 – RESOLUTION TO GRANT DISCHARGE OF...

BEIJING, China, April 04, 2024 (GLOBE NEWSWIRE) — Niu Technologies (“NIU”, or “the Company”) (NASDAQ: NIU), the world’s leading provider of smart urban mobility solutions, today provides its sales volume results for the first quarter of 2024.  1Q 2024   1Q 2023   YoY%  China Market 110,115   81,518   35%  International Markets 19,024   12,889   48%  Total 129,139   94,407   37%  In the first quarter of 2024, NIU sold 129,139 units, with 110,115 units sold in China market and 19,024 units sold in international markets. In the domestic market, our new products have captured significant mindshare since their launch, collectively accounting for over 50% of the total sales volume in the first quarter. Notably, our premium flagship model NXT contributed 26% to the total domestic sales. This model builds upon and seamlessly...